The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia

By Ben-Hamadi R.   Duh M. S.   Aggarwal J.   Henckler A.   Mckenzie R. S.   Tak Piech C.  

Current Medical Research and Opinion, Vol. 21, Iss. 10, 2005-10 ,pp. : 1677-1682

Informa Healthcare

Access to resources Recommend Favorite

Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia

By Henry David H.   Gordan Lucio N.   Charu Veena   Wilhelm Francois E.   Williams Denise   Xie John   Woodman Richard C.  

Current Medical Research and Opinion, Vol. 22, Iss. 7, 2006-07 ,pp. : 1403-1413

Informa Healthcare

Access to resources Recommend Favorite

Comments on Clinical and economic comparison of epoetin alfa and darbepoetin alfa

By Vanscoy Gordon J.   Sullivan Sean D.   Morreale Anthony P.  

Current Medical Research and Opinion, Vol. 20, Iss. 9, 2004-09 ,pp. : 1459-1463

Informa Healthcare

Access to resources Recommend Favorite

A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia

By Kotasek Dusan   Canon Jean-Luc   Mateos Maria Victoria   Hedenus Michael   Rossi Greg   Taylor Kerry  

Current Medical Research and Opinion, Vol. 23, Iss. 6, 2007-06 ,pp. : 1387-1401

Informa Healthcare

Access to resources Recommend Favorite

HX575, Recombinant Human Epoetin Alfa, for the Treatment of Chemotherapy-Associated Symptomatic Anaemia in Patients with Solid Tumours

By  

Oncology Research and Treatment, Vol. 32, Iss. 4, 2009-03 ,pp. : 168-174

Karger

Access to resources Recommend Favorite